These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 35264311)
21. Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Viljoen A; Hoxer CS; Johansen P; Malkin S; Hunt B; Bain SC Diabetes Obes Metab; 2019 Mar; 21(3):611-621. PubMed ID: 30362224 [TBL] [Abstract][Full Text] [Related]
22. Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. Risebrough NA; Baker TM; Zhang L; Ali SN; Radin M; Dang-Tan T Clin Ther; 2021 Nov; 43(11):1812-1826.e7. PubMed ID: 34728099 [TBL] [Abstract][Full Text] [Related]
23. Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER). Matza LS; Boye KS; Stewart KD; Coyne KS; Wullenweber PK; Cutts KN; Jordan JB; Wang Q; Yu M; Currie BM; Malley KG; Ishak KJ; Hietpas RT; García-Pérez LE Diabetes Obes Metab; 2020 Mar; 22(3):355-364. PubMed ID: 31646727 [TBL] [Abstract][Full Text] [Related]
24. The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in patients with type 2 diabetes (TROPHIES): Final, 24-month analysis of time to first significant treatment change, treatment persistence and clinical outcomes. Giorgino F; Guerci B; Füchtenbusch M; Lebrec J; Boye K; Orsini Federici M; Heitmann E; Dib A; Yu M; Sapin H; García-Pérez LE Diabetes Obes Metab; 2023 Dec; 25(12):3465-3477. PubMed ID: 37700627 [TBL] [Abstract][Full Text] [Related]
25. A model-based simulation of glycaemic control and body weight when switching from semaglutide to 3.0- and 4.5-mg doses of once-weekly dulaglutide. Tham LS; Pantalone KM; Dungan K; Munir K; Tang CC; Konig M; Kwan AYM Diabetes Obes Metab; 2022 Feb; 24(2):302-311. PubMed ID: 34697882 [TBL] [Abstract][Full Text] [Related]
26. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months. Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235 [TBL] [Abstract][Full Text] [Related]
27. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. Hunt B; Malkin SJP; Moes RGJ; Huisman EL; Vandebrouck T; Wolffenbuttel BHR BMJ Open Diabetes Res Care; 2019; 7(1):e000705. PubMed ID: 31641522 [TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same? Gentilella R; Pechtner V; Corcos A; Consoli A Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747 [TBL] [Abstract][Full Text] [Related]
29. Impact of semaglutide and dulaglutide shortages on Pharmaceutical Benefits Scheme prescriptions supplied for type 2 diabetes treatment. Phakey S; Shen A Aust J Gen Pract; 2024; 53(1-2):57-61. PubMed ID: 38316483 [TBL] [Abstract][Full Text] [Related]
30. A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. Evans LM; Mellbin L; Johansen P; Lawson J; Paine A; Sandberg A Endocrinol Diabetes Metab; 2021 Jul; 4(3):e00259. PubMed ID: 34277983 [TBL] [Abstract][Full Text] [Related]
31. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study. Barrett A; Debackere N; Ribeiro A; Keapoletswe K; Zingel R; Coles B Adv Ther; 2023 Aug; 40(8):3446-3464. PubMed ID: 37286889 [TBL] [Abstract][Full Text] [Related]
32. Use of Dulaglutide, Semaglutide, and Tirzepatide in Diabetes and Weight Management. Powell J; Taylor J Clin Ther; 2024 Mar; 46(3):289-292. PubMed ID: 38310052 [TBL] [Abstract][Full Text] [Related]
33. Real-life experience with Dulaglutide: Analysis of clinical effectiveness to 24 months. Moreno Obregón F; Miramontes-González JP; Romo Guajardo-Fajardo C; Nieto-Sánchez Á; López-Suárez JM; Martín-Vallejo J; Arco-Prados Y; Dolores García de Lucas M; León-Jiménez D Diabetes Res Clin Pract; 2019 Dec; 158():107916. PubMed ID: 31682882 [TBL] [Abstract][Full Text] [Related]
34. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Germany: a retrospective cohort study. Otto T; Myland M; Jung H; Lebrec J; Richter H; Norrbacka K Curr Med Res Opin; 2019 May; 35(5):893-901. PubMed ID: 30328731 [TBL] [Abstract][Full Text] [Related]
36. Dulaglutide for the treatment of type 2 diabetes. Scheen AJ Expert Opin Biol Ther; 2017 Apr; 17(4):485-496. PubMed ID: 28274140 [TBL] [Abstract][Full Text] [Related]
37. Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. Cukierman-Yaffe T; Gerstein HC; Colhoun HM; Diaz R; García-Pérez LE; Lakshmanan M; Bethel A; Xavier D; Probstfield J; Riddle MC; Rydén L; Atisso CM; Hall S; Rao-Melacini P; Basile J; Cushman WC; Franek E; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Pirags V; Pogosova N; Raubenheimer PJ; Shaw JE; Sheu WH; Temelkova-Kurktschiev T Lancet Neurol; 2020 Jul; 19(7):582-590. PubMed ID: 32562683 [TBL] [Abstract][Full Text] [Related]
38. Monotherapy with the once weekly GLP-1 receptor agonist dulaglutide for 12 weeks in Japanese patients with type 2 diabetes: dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Terauchi Y; Satoi Y; Takeuchi M; Imaoka T Endocr J; 2014; 61(10):949-59. PubMed ID: 25029955 [TBL] [Abstract][Full Text] [Related]
39. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Skrivanek Z; Gaydos BL; Chien JY; Geiger MJ; Heathman MA; Berry S; Anderson JH; Forst T; Milicevic Z; Berry D Diabetes Obes Metab; 2014 Aug; 16(8):748-56. PubMed ID: 24762094 [TBL] [Abstract][Full Text] [Related]
40. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy. Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]